<DOC>
	<DOCNO>NCT00002952</DOCNO>
	<brief_summary>RATIONALE : Vaccines make tumor antigen gene may make body build immune response kill tumor cell . Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's white blood cell kill melanoma cell . Combining vaccine therapy interleukin-12 may kill melanoma cell . PURPOSE : Phase I/II trial study effectiveness vaccine therapy plus interleukin-12 treating patient metastatic melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Interleukin-12 Treating Patients With Metastatic Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety maximum tolerate dose level vaccine consist MAGE-3 Melan-A ( human tumor antigen gene ) peptide-pulsed autologous peripheral blood mononuclear cell plus interleukin-12 . II . Determine procedure result successful immunization . III . Assess response tumor vaccine . OUTLINE : This open label , nonrandomized , single institution study . Patients receive 3 initial course treatment consist 21 day . Treatment consist immunization MAGE-3 Melan-A peptide-loaded autologous PBMC interleukin-12 ( IL-12 ) first day , IL-12 day 3 5 , 16 day rest . The first cohort administer IL-12 next cohort give escalate dos IL-12 . The Phase II dose one dose level MTD . Patients tumor remission response stable disease may continue treatment one year . Phase I complete 04/1999 . Patients follow every 3 month . PROJECTED ACCRUAL : A total 34 patient accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma Patient must express HLAA2 ( human leukocyte antigen ) Tumor must express MAGE3 MelanA polymerase chain reaction ( PCR ) analysis No untreated brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70 % 100 % Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) SGPT great 2 time ULN Renal : Calcium great 11 mg/dL Creatinine great 1.5 time ULN Cardiovascular : No significant cardiovascular disease cardiac arrhythmia require medical intervention Other : Hepatitis B surface antigen negative HIV negative No serious concurrent infection No clinically significant autoimmune disease No active gastrointestinal bleeding uncontrolled peptic ulcer disease No history inflammatory bowel disease No psychiatric illness may interfere compliance study Not pregnant nursing PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunosuppressive drug At least 4 week since biologic therapy Chemotherapy : At least 2 week since chemotherapy Endocrine therapy : No concurrent systemic corticosteroid ( except physiologic replacement dos ) Radiotherapy : At least 2 week since radiotherapy Surgery : At least 2 week since surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>